1
|
Peng X, Holler CJ, Alves AMF, Oliviera MG, Speake M, Pugliese A, Oskouei MR, de Freitas ID, Chen AYP, Gallegos R, McTighe SM, Koenig G, Hurst RS, Blain JF, Lanter JC, Burnett DA. Discovery and characterization of novel TRPML1 agonists. Bioorg Med Chem Lett 2024; 98:129595. [PMID: 38141860 DOI: 10.1016/j.bmcl.2023.129595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 11/30/2023] [Accepted: 12/17/2023] [Indexed: 12/25/2023]
Abstract
Screening a library of >100,000 compounds identified the substituted tetrazole compound 1 as a selective TRPML1 agonist. Both enantiomers of compound 1 were separated and profiled in vitro and in vivo. Their selectivity, ready availability and CNS penetration should enable them to serve as the tool compounds of choice in future TRPML1 channel activation studies. SAR studies on conformationally locked macrocyclic analogs further improved the TRPML1 agonist potency while retaining the selectivity.
Collapse
Affiliation(s)
- Xiaowen Peng
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA.
| | | | - Anna-Maria F Alves
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Michelle G Oliviera
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Michael Speake
- BioAscent Discovery Ltd, Bo'Ness Rd, Chapelhall, Motherwell ML1 5UH, United Kingdom
| | - Angelo Pugliese
- BioAscent Discovery Ltd, Bo'Ness Rd, Chapelhall, Motherwell ML1 5UH, United Kingdom
| | - Mina R Oskouei
- Symeres Inc, Kerkenbos 1013, 6546 BB Nijmegen, the Netherlands
| | | | - Angela Y-P Chen
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Richard Gallegos
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Stephanie M McTighe
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Gerhard Koenig
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Raymond S Hurst
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Jean-François Blain
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - James C Lanter
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Duane A Burnett
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| |
Collapse
|
2
|
Visvikis O, Ihuegbu N, Labed SA, Luhachack LG, Alves AMF, Wollenberg AC, Stuart LM, Stormo GD, Irazoqui JE. Innate host defense requires TFEB-mediated transcription of cytoprotective and antimicrobial genes. Immunity 2014; 40:896-909. [PMID: 24882217 DOI: 10.1016/j.immuni.2014.05.002] [Citation(s) in RCA: 217] [Impact Index Per Article: 21.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2013] [Accepted: 04/08/2014] [Indexed: 10/25/2022]
Abstract
Animal host defense against infection requires the expression of defense genes at the right place and the right time. Understanding such tight control of host defense requires the elucidation of the transcription factors involved. By using an unbiased approach in the model Caenorhabditis elegans, we discovered that HLH-30 (known as TFEB in mammals) is a key transcription factor for host defense. HLH-30 was activated shortly after Staphylococcus aureus infection, and drove the expression of close to 80% of the host response, including antimicrobial and autophagy genes that were essential for host tolerance of infection. TFEB was also rapidly activated in murine macrophages upon S. aureus infection and was required for proper transcriptional induction of several proinflammatory cytokines and chemokines. Thus, our data suggest that TFEB is a previously unappreciated, evolutionarily ancient transcription factor in the host response to infection.
Collapse
Affiliation(s)
- Orane Visvikis
- Laboratory of Comparative Immunology, Center for the Study of Inflammatory Bowel Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
| | - Nnamdi Ihuegbu
- Department of Genetics, Center for Genome Sciences, Washington University Medical School, Saint Louis, Missouri 63118, USA
| | - Sid A Labed
- Laboratory of Comparative Immunology, Center for the Study of Inflammatory Bowel Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
| | - Lyly G Luhachack
- Laboratory of Comparative Immunology, Center for the Study of Inflammatory Bowel Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
| | - Anna-Maria F Alves
- Laboratory of Comparative Immunology, Center for the Study of Inflammatory Bowel Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
| | - Amanda C Wollenberg
- Laboratory of Comparative Immunology, Center for the Study of Inflammatory Bowel Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
| | - Lynda M Stuart
- Bill and Melinda Gates Foundation, Seattle, Washington 98109, USA
| | - Gary D Stormo
- Department of Genetics, Center for Genome Sciences, Washington University Medical School, Saint Louis, Missouri 63118, USA
| | - Javier E Irazoqui
- Laboratory of Comparative Immunology, Center for the Study of Inflammatory Bowel Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
| |
Collapse
|